Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Cream in Hidradenitis Suppurativa
NCT06959225Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Jun 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Ruxolitinib 1.5 % Cream with Vehicle Cream (2 arms). Primary endpoint: Hidradenitis Suppurativa Clinical Response 75 at 16 weeks. Started Jun 2025; status: active, not recruiting.
02
Drugs
ruxolitinib cream
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06959225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06959225.